CDB Capital-backed TCM Healthcare Fund of Guangdong, an investment company, led a $107m funding round in HighTide Therapeutics, a global clinical-stage biopharmaceutical company, with participation from Yuexiu Fund and Yuthai Fund. "After completing a successful $60m Series B+ round at the end of 2020, we are thrilled to have well-recognized investors participate in our C/C+ round. We are grateful that our investors have such strong confidence in HighTide's team, the commercial value of our pipeline, and future development prospects. The Series C/C+ financing is a significant milestone for HighTide. It will enable us to move aggressively to accelerate the clinical and commercial development of our innovative pipeline and external business collaborations," Liping Liu, HighTide Founder and CEO.